MCID: PRT029
MIFTS: 50

Parathyroid Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Parathyroid Adenoma

MalaCards integrated aliases for Parathyroid Adenoma:

Name: Parathyroid Adenoma 12 54 6 15 17 71
Adenoma of the Parathyroid Gland 12
Adenoma of Parathyroid 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7608
MeSH 43 D010282
NCIt 49 C3916
SNOMED-CT 67 128474007
UMLS 71 C0262587

Summaries for Parathyroid Adenoma

Disease Ontology : 12 A parathyroid gland benign neoplam that is located in the parathyroid.

MalaCards based summary : Parathyroid Adenoma, also known as adenoma of the parathyroid gland, is related to hyperparathyroidism 1 and hyperparathyroidism 2 with jaw tumors. An important gene associated with Parathyroid Adenoma is CDC73 (Cell Division Cycle 73), and among its related pathways/superpathways are Signaling by GPCR and Mesodermal Commitment Pathway. The drugs Cinacalcet and Alendronate have been mentioned in the context of this disorder. Affiliated tissues include parathyroid, thyroid and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 A parathyroid adenoma is a benign tumor of the parathyroid gland. It generally causes... more...

Related Diseases for Parathyroid Adenoma

Diseases related to Parathyroid Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 419)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 1 34.1 MEN1 GCM2 CDC73
2 hyperparathyroidism 2 with jaw tumors 33.8 RET MEN1 CDC73 CCND1 CASR
3 osteitis fibrosa 32.8 PTH CDC73 CASR CALCA BGLAP
4 multiple endocrine neoplasia, type iia 32.8 RET PTH MEN1 CDC73 CALCA
5 multiple endocrine neoplasia 32.7 RET PRKAR1A MEN1 CALCA
6 parathyroid carcinoma 32.7 RET PTH MEN1 CDC73 CCND1 CASR
7 adenoma 31.3 TSC1 RET PTH PRKAR1A MEN1 IGF1
8 multinodular goiter 31.1 RET PTH CALCA
9 goiter 31.1 RET IGF1 CALCA BGLAP
10 hypophosphatemia 31.1 VDR PTHLH PTH BGLAP
11 clear cell adenoma 31.1 PTH CDC73
12 nephrolithiasis 31.0 VDR PTH MEN1 CASR BGLAP
13 thyroid gland medullary carcinoma 30.9 RET MEN1 CHGA CALCA
14 urolithiasis 30.8 VDR CASR BGLAP
15 hyperthyroidism 30.8 PTH IGF1 CALCA BGLAP ALPP
16 pituitary adenoma 30.8 PRKAR1A MEN1 IGF1 CHGA
17 follicular adenoma 30.8 RET MEN1 CALCA
18 primary hyperparathyroidism 30.7 VDR RET PTHLH PTH PRKAR1A MEN1
19 parathyroid transitional clear cell adenoma 30.7 PTH MEN1
20 thyroid gland disease 30.7 RET PTH IGF1 CALCA
21 constipation 30.6 RET PTH CHGA CALCA
22 myeloma, multiple 30.6 PTHLH PTH IGF1 CTNNB1 CCND1 BGLAP
23 hyperprolactinemia 30.6 PTHLH PTH IGF1
24 secondary hyperparathyroidism 30.6 VDR PTH MEN1 CASR CALCA BGLAP
25 hypocalciuric hypercalcemia, familial, type i 30.6 PTH CDC73 CASR
26 rickets 30.5 VDR PTH CASR CALCA BGLAP ALPP
27 oncogenic osteomalacia 30.5 PTHLH PTH
28 thyroid carcinoma, familial medullary 30.5 RET PRKAR1A MEN1 CHGA CALCA
29 hemangioma 30.5 RET MEN1 CTNNB1 CHGA
30 gastrinoma 30.5 MEN1 CHGA CASR
31 hyperparathyroidism, neonatal severe 30.4 PRKAR1A CASR
32 pancreatic gastrinoma 30.4 MEN1 CHGA
33 multiple endocrine neoplasia, type i 30.4 RET PTH PRKAR1A MEN1 CHGA CDKN2C
34 paraganglioma 30.4 RET MEN1 CHGA CALCA
35 invasive malignant thymoma 30.4 PTHLH PTH
36 fibroma 30.4 TSC1 CTNNB1 CDC73
37 calciphylaxis 30.3 VDR PTH CASR
38 pancreatic cholera 30.3 MEN1 CHGA CALCA
39 pheochromocytoma 30.3 RET MEN1 IGF1 CHGA CDKN2C CCND1
40 neuroendocrine tumor 30.3 RET MEN1 CHGA CALCA
41 vipoma 30.3 MEN1 CHGA CALCA
42 chronic kidney disease 30.3 VDR PTH IGF1 CASR BGLAP
43 suppression of tumorigenicity 12 30.2 IGF1 CTNNB1 CHGA CCND1
44 lung oat cell carcinoma 30.2 CHGA CALCA
45 acromegaly 30.2 PRKAR1A MEN1 IGF1 BGLAP
46 familial hypocalciuric hypercalcemia 30.2 RET PTHLH PTH MEN1 GCM2 CDC73
47 meningioma, familial 30.2 RET PRKAR1A MEN1 IGF1 CTNNB1 CCND1
48 hypercalcemia, infantile, 1 30.2 VDR PTHLH PTH CASR CALCA
49 uremia 30.2 VDR PTH MEN1 CASR
50 fibrous dysplasia 30.2 PTHLH IGF1 CDC73 CALCA BGLAP

Graphical network of the top 20 diseases related to Parathyroid Adenoma:



Diseases related to Parathyroid Adenoma

Symptoms & Phenotypes for Parathyroid Adenoma

GenomeRNAi Phenotypes related to Parathyroid Adenoma according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.8 BGLAP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.8 IGF1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-119 9.8 BGLAP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.8 PRKAR1A
5 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.8 BGLAP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.8 RET
7 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.8 IGF1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.8 IGF1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.8 BGLAP
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.8 IGF1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.8 IGF1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.8 BGLAP IGF1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.8 BGLAP
14 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.8 BGLAP
15 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.8 IGF1 RET
16 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.8 BGLAP
17 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.8 BGLAP
18 Increased shRNA abundance (Z-score > 2) GR00366-A-193 9.8 IGF1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.8 PRKAR1A
20 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.8 IGF1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.8 RET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.8 RET
23 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.8 IGF1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.8 RET
25 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.8 RET
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.8 RET
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.8 RET
28 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.8 IGF1
29 Decreased viability GR00221-A-1 9.77 CDKN2C RET
30 Decreased viability GR00221-A-2 9.77 RET TSC1
31 Decreased viability GR00221-A-3 9.77 TSC1
32 Decreased viability GR00221-A-4 9.77 RET
33 Decreased viability GR00249-S 9.77 CDKN2C CDKN2D
34 Decreased viability GR00301-A 9.77 CDKN2C CDKN2D RET TSC1
35 Decreased viability GR00402-S-2 9.77 RET

MGI Mouse Phenotypes related to Parathyroid Adenoma:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 BGLAP CASR CCND1 CDC73 CDKN2C CDKN2D
2 endocrine/exocrine gland MP:0005379 10.47 BGLAP CASR CCND1 CDC73 CDKN2C CDKN2D
3 growth/size/body region MP:0005378 10.4 CASR CCND1 CDC73 CDKN2C CDKN2D CHGA
4 homeostasis/metabolism MP:0005376 10.4 BGLAP CASR CCND1 CDC73 CDKN2C CDKN2D
5 cardiovascular system MP:0005385 10.39 CCND1 CDC73 CDKN2C CHGA CTNNB1 IGF1
6 mortality/aging MP:0010768 10.34 CASR CCND1 CDC73 CDKN2C CDKN2D CHGA
7 hematopoietic system MP:0005397 10.29 BGLAP CASR CCND1 CDC73 CDKN2C CTNNB1
8 immune system MP:0005387 10.29 BGLAP CASR CCND1 CDC73 CDKN2C CTNNB1
9 craniofacial MP:0005382 10.21 CCND1 CDC73 CTNNB1 GCM2 MEN1 PRKAR1A
10 digestive/alimentary MP:0005381 10.2 CASR CCND1 CDC73 CTNNB1 MEN1 PRKAR1A
11 integument MP:0010771 10.16 CASR CCND1 CDC73 CDKN2C CTNNB1 IGF1
12 muscle MP:0005369 10.14 CASR CDC73 CDKN2D CHGA CTNNB1 IGF1
13 nervous system MP:0003631 10.13 CCND1 CDC73 CDKN2C CDKN2D CHGA CTNNB1
14 neoplasm MP:0002006 10.11 CCND1 CDC73 CDKN2C CDKN2D CTNNB1 IGF1
15 renal/urinary system MP:0005367 10 CASR CDC73 CDKN2C CHGA CTNNB1 GCM2
16 reproductive system MP:0005389 10 BGLAP CCND1 CDC73 CDKN2C CDKN2D CHGA
17 respiratory system MP:0005388 9.65 CCND1 CDC73 CDKN2C CDKN2D CTNNB1 IGF1
18 skeleton MP:0005390 9.4 BGLAP CASR CCND1 CDC73 CTNNB1 GCM2

Drugs & Therapeutics for Parathyroid Adenoma

Drugs for Parathyroid Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cinacalcet Approved Phase 4 226256-56-0 156419
2
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
3
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
4
Calcitonin gene-related peptide Investigational Phase 4 83652-28-2
5 Hormones Phase 4
6 Calcium, Dietary Phase 4
7 Hormone Antagonists Phase 4
8 Vasodilator Agents Phase 4
9 Katacalcin Phase 4
10 calcitonin Phase 4
11
Calcium Nutraceutical Phase 4 7440-70-2 271
12
Parathyroid hormone Approved, Investigational Phase 3 9002-64-6
13
Denosumab Approved Phase 3 615258-40-7
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
15
Choline Approved, Nutraceutical Phase 3 62-49-7 305
16 Vitamins Phase 3
17 Calciferol Phase 3
18 Technetium Tc 99m Sestamibi Phase 3
19 Hypolipidemic Agents Phase 3
20 Lipid Regulating Agents Phase 3
21 Gastrointestinal Agents Phase 3
22 Antimetabolites Phase 3
23 Radiopharmaceuticals
24 Dermatologic Agents
25 Sodium Pertechnetate Tc 99m

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
2 Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan With Calcitonin Pre-treatment for Primary Hyperparathyroidism Recruiting NCT03935984 Phase 4 Calcitonin
3 Clinical Value of 18F -Fluorocholine (18F-FCH) PET in Localizing Parathyroid Lesions: Comparison With 99mTc-sestamibi (MIBI) Scan. Completed NCT03555487 Phase 3 18F-choline PET
4 Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Completed NCT03027557 Phase 3 Cinacalcet 30 mg Tablet;Denosumab Inj 60 mg/ml
5 Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention Recruiting NCT04040946 Phase 3
6 Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas Completed NCT02432599 Phase 2
7 Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma Unknown status NCT01221896
8 Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination Unknown status NCT01084356
9 Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study Unknown status NCT02843542
10 A Novel Approach to Ultrafast Parathyroid SPECT Imaging Using a Solid State CZT SPECT Camera Unknown status NCT01226810
11 Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules Unknown status NCT03309631
12 Transcriptional and Translational Regulation of Vitamin D Receptor (VDR) and Calcium Sensing Receptor (CaSR) in Patients With Sporadic Primary Hyperparathyroidism Unknown status NCT01228786
13 Open Compared to Video-Assisted Minimal-Invasive Parathyroid Surgery in Primary Hyperparathyroidism Completed NCT00877981
14 Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC Completed NCT01574287 FACBC
15 Use of Hypocalcemic Intraarterial Infusion Into the Thyroid/Parathyroid Bed to Localize Occult Parathyroid Adenomas Completed NCT00001394
16 18F-Fluorocholine PET/CT in the Pre-operative Localization of Hyperfunctional Parathyroid Gland in Primary and Secondary Hyperparathyroidism Completed NCT04316845
17 Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism Recruiting NCT03605472
18 Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents Recruiting NCT03039439
19 Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging Recruiting NCT04344886
20 Family Studies in Metabolic Diseases and Mineral Metabolism Recruiting NCT00001345
21 Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy Recruiting NCT04299425
22 Comparison of CEUS With Conventional Ultrasound (US) to Dual-tracer 99mTcO4-/99mTc-MIBI Subtraction Scintigraphy With SPECT/CT Combined With US for Localizing Pathological Parathyroid Glands in Patients With Primary Hyperparathyroidism Recruiting NCT04305561
23 Ultrasound Guided Fine Needle Aspiration of Parathyroid Gland as a Pre Operative Localization Tool to Identify Pathological Parathyroid Not yet recruiting NCT03516747
24 High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma Terminated NCT01291498
25 Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism Terminated NCT00639405
26 Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism Withdrawn NCT02381925

Search NIH Clinical Center for Parathyroid Adenoma

Genetic Tests for Parathyroid Adenoma

Anatomical Context for Parathyroid Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Parathyroid Adenoma:

19
Parathyroid

MalaCards organs/tissues related to Parathyroid Adenoma:

40
Thyroid, Bone, Breast, Testes, Kidney, Lung, Pituitary

Publications for Parathyroid Adenoma

Articles related to Parathyroid Adenoma:

(show top 50) (show all 3648)
# Title Authors PMID Year
1
Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. 61 6
16720667 2006
2
Calcium-sensing receptor autoantibodies in primary hyperparathyroidism. 54 61
19520070 2009
3
Association of parathyroid adenoma and familial hypocalciuric hypercalcaemia in a teenager. 61 54
19423559 2009
4
Diagnosis and surgical treatment of multiple endocrine neoplasia. 61 54
19719936 2009
5
Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. 54 61
18755853 2008
6
Chromosome 11 genomic changes in parathyroid adenoma and hyperplasia: array CGH, FISH, and tissue microarrays. 61 54
18398822 2008
7
Substernal oxyphil parathyroid adenoma producing PTHrP with hypercalcemia and normal PTH level. 61 54
18291038 2008
8
Mutational analysis of the PTH 3'-untranslated region in parathyroid disorders. 54 61
17121534 2006
9
Immunohistochemical assessment of parafibromin in mouse and human tissues. 61 54
17118068 2006
10
Primary hyperparathyroidism with a low-normal, atypical serum parathyroid hormone as shown by discordant immunoassay curves. 54 61
16849415 2006
11
Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease. 54 61
16882790 2006
12
HRPT2 gene alterations in ossifying fibroma of the jaws. 61 54
16458039 2006
13
Genetic aberrance of sporadic MEN 2A component tumours: analysis of RET. 54 61
15875728 2005
14
Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics. 54 61
15754732 2004
15
Minireview: Cyclin D1: normal and abnormal functions. 54 61
15331580 2004
16
Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism. 61 54
15356052 2004
17
Primary hyperparathyroidism associatiated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. 61 54
15168774 2004
18
Recurrent hypercalcemia due to ectopic production of parathyroid hormone-related protein and intact parathyroid hormone in a single patient with multiple malignancies. 61 54
15256329 2004
19
Immunohistochemical detection of cell cycle regulators, Fhit protein and apoptotic cells in parathyroid lesions. 54 61
12534361 2003
20
Preoperative diagnosis of suspicious parathyroid adenomas by RT-PCR using mRNA extracted from leftover cells in a needle used for ultrasonically guided fine needle aspiration cytology. 54 61
12585024 2003
21
Exclusive underexpression of vitamin D receptor exon 1f transcripts in tumors of primary hyperparathyroidism. 54 61
12444900 2002
22
Using technetium 99m tetrofosmin parathyroid imaging to detect parathyroid adenoma and its relation to P-glycoprotein expression. 61 54
12324759 2002
23
Technetium-99m methoxyisobutylisonitrile imaging for parathyroid adenoma: relationship to P-glycoprotein or multidrug resistance-related protein expression. 61 54
12173014 2002
24
Detecting parathyroid adenoma using technetium-99m tetrofosmin: comparison with P-glycoprotein and multidrug resistance related protein expression--a preliminary report. 54 61
11929704 2002
25
Immunohistochemistry of cyclin D1 and beta-catenin, and mutational analysis of exon 3 of beta-catenin gene in parathyroid adenomas. 54 61
11836555 2002
26
Correlation between P-glycoprotein (P-gp) expression in parathyroid and Tc-99m MIBI parathyroid image findings. 54 61
11711312 2001
27
Genetic analysis of a papillary thyroid carcinoma in a patient with MEN1. 54 61
11352308 2001
28
Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. 61 54
11290553 2001
29
Molecular pathology of parathyroid tumors. 61 54
11167122 2001
30
The role of hyperplasia in multiple parathyroid adenomas. 61 54
11303630 2001
31
Pancreastatin plasma levels in patients with primary hyperparathyroidism. 61 54
11193727 2000
32
A newly recognized germline mutation of MEN1 gene identified in a patient with parathyroid adenoma and carcinoma. 61 54
10963041 2000
33
Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. 61 54
10843188 2000
34
Cyclin D1 in parathyroid disease. 61 54
10704427 2000
35
Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. 54 61
10720039 2000
36
Identification of a novel activated form of the keratinocyte growth factor receptor by expression cloning from parathyroid adenoma tissue. 54 61
10523826 1999
37
Relationship between Ca-dependent change of serum PTH and extracellular Ca2+-sensing receptor expression in parathyroid adenoma. 61 54
10024390 1999
38
Mechanism of parathyroid tumourigenesis in uraemia. 61 54
10048455 1999
39
Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. 61 54
10548885 1999
40
Primary hyperparathyroidism-associated polyostotic fibrous dysplasia: absence of McCune-Albright syndrome mutations. 61 54
9413810 1997
41
Vitamin D receptor polymorphisms correlate to parathyroid cell function in primary hyperparathyroidism. 54 61
9177380 1997
42
Parathyroid function and histology in patients with parathyroid adenoma: correlation of clinical and morphologic findings. 61 54
9204747 1997
43
Co-secretion of parathyroid hormone and parathyroid-hormone-related protein via a regulated pathway in human parathyroid adenoma cells. 61 54
9060824 1997
44
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 61 54
8636377 1996
45
Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. 54 61
7621424 1995
46
Inhibition of parathyroid hormone-related protein release by extracellular calcium in dispersed cells from human parathyroid hyperplasia secondary to chronic renal failure and adenoma. 61 54
7778690 1995
47
Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. 61 54
7759551 1995
48
P-glycoprotein is expressed in parathyroid epithelium and is regulated by calcium. 61 54
7736328 1995
49
Clonal analysis of parathyroid adenomas by means of the polymerase chain reaction. 61 54
7910112 1994
50
Light microscopical immunohistochemical study on parathyroid adenoma in primary hyperparathyroidism. 54 61
7515533 1994

Variations for Parathyroid Adenoma

ClinVar genetic disease variations for Parathyroid Adenoma:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MEN1 NM_000244.3(MEN1):c.371_372del (p.Val124fs)deletion Pathogenic 523339 rs1555166368 11:64577210-64577211 11:64809738-64809739
2 CDC73 NM_024529.4(CDC73):c.679_680AG[3] (p.Arg229fs)short repeat Pathogenic 3278 1:193111146-193111149 1:193142016-193142019
3 MEN1 NM_000244.3(MEN1):c.669+1deldeletion Pathogenic 374107 rs1057518903 11:64575362-64575362 11:64807890-64807890
4 CASR NM_000388.4(CASR):c.2449G>A (p.Val817Ile)SNV Likely pathogenic 374153 rs1057518933 3:122003250-122003250 3:122284403-122284403

Copy number variations for Parathyroid Adenoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25580 1 191357783 191487679 Loss HRPT2 Parathyroid adenoma
2 33979 1 51206195 51212897 Loss CDKN2C Parathyroid adenoma
3 33993 1 51300000 56200000 Loss RNF11 Parathyroid adenoma
4 48482 11 1 48800000 Losse MEN1 Parathyroid adenoma
5 192952 5 121500000 127300000 Gaine LMNB1 Parathyroid adenoma
6 192953 5 121500000 127300000 Gaine PIK3R1 Parathyroid adenoma

Expression for Parathyroid Adenoma

Search GEO for disease gene expression data for Parathyroid Adenoma.

Pathways for Parathyroid Adenoma

GO Terms for Parathyroid Adenoma

Cellular components related to Parathyroid Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.17 VDR PTH MEN1 GCM2 CTNNB1 CASR

Biological processes related to Parathyroid Adenoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 VDR PTH MEN1 IGF1 GCM2 CTNNB1
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.04 VDR PTH MEN1 CTNNB1 CDC73 CCND1
3 positive regulation of cell proliferation GO:0008284 9.98 PTHLH IGF1 CTNNB1 CCND1 CASR
4 positive regulation of gene expression GO:0010628 9.96 VDR RET IGF1 CTNNB1 CASR
5 response to drug GO:0042493 9.88 RET PTH CTNNB1 CCND1 BGLAP
6 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.7 CDKN2D CDKN2C CDC73
7 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.69 CDKN2D CDKN2C CCND1
8 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.61 MEN1 CDKN2D CDKN2C
9 regulation of osteoclast differentiation GO:0045670 9.6 CTNNB1 BGLAP
10 cellular response to vitamin D GO:0071305 9.59 CASR BGLAP
11 negative regulation of cell cycle G1/S phase transition GO:1902807 9.58 MEN1 CDKN2D
12 beta-catenin-TCF complex assembly GO:1904837 9.58 MEN1 CTNNB1 CDC73
13 cellular calcium ion homeostasis GO:0006874 9.55 VDR PTH GCM2 CASR CALCA
14 response to fibroblast growth factor GO:0071774 9.54 PTH CASR
15 negative regulation of chondrocyte differentiation GO:0032331 9.54 PTHLH PTH CTNNB1
16 osteoblast development GO:0002076 9.5 PTHLH MEN1 BGLAP
17 endodermal cell fate commitment GO:0001711 9.49 CTNNB1 CDC73
18 cAMP metabolic process GO:0046058 9.46 PTHLH PTH
19 response to vitamin D GO:0033280 9.43 PTH CDKN2D BGLAP
20 skeletal system development GO:0001501 9.43 VDR PTHLH PTH IGF1 CTNNB1 BGLAP
21 negative regulation of cell proliferation GO:0008285 9.23 VDR TSC1 PTHLH MEN1 CTNNB1 CDKN2D

Molecular functions related to Parathyroid Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 CTNNB1 CDKN2D CDKN2C CCND1 CASR
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2D CDKN2C
3 peptide hormone receptor binding GO:0051428 8.96 PTHLH PTH
4 hormone activity GO:0005179 8.92 PTHLH PTH IGF1 CALCA

Sources for Parathyroid Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....